NCT06146777View on ClinicalTrials.gov

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

468

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

December 1, 2030

Study Completion Date

December 1, 2030

Conditions

Papillary Renal Cell Carcinoma

Interventions

DRUG

Pembrolizumab

Intravenous infusion

DRUG

Placebo

Intravenous infusion

All Listed Sponsors

lead

First Affiliated Hospital, Sun Yat-Sen University

OTHER